366 – Impact of the TKI Dasatinib on T-Cell Effector Functions in ART-Suppressed PWH (BCN04-DASA)
Background Dasatinib (DASA), a tyrosine kinase inhibitor (TKI) used to treat chronic myeloid leukemia, may help promote HIV-1 latency and reduce immune activation and senescence. However, DASA could impact T-cell effector functions by inhibition of TCR proximal kinases. Its impact on antigen-specific responses in people with HIV (PWH) is unclear. We evaluated the impact of low-dose…